TMEM232: A Transmembrane Protein for Drug Targets and Biomarkers

Target Name: TMEM232

NCBI ID: G642987

TMEM232

Other Name(s): Transmembrane protein 232 | transmembrane protein 232 | TM232_HUMAN

TMEM232: A Transmembrane Protein for Drug Targets and Biomarkers

TMEM232 (Transmembrane protein 232) is a protein that has been identified as a potential drug target and biomarker. It is a member of the transmembrane protein (TMEM) family, which is known for their unique structure and function in various organisms. TMEM232 is expressed in a variety of tissues and has been shown to play a role in various physiological processes, including cell signaling, migration, and invasion.

The Discovery and Characterization of TMEM232

TMEM232 was first identified in the late 1990s as a protein that was expressed in various tissues, including brain, heart, and pancreas. It was shown to localize to the endoplasmic reticulum (ER) and to interact with various cellular signaling pathways, including the TGF-β pathway.

In addition to its potential drug target properties, TMEM232 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its unique expression pattern and the presence of various post-translational modifications (PTMs), such as phosphorylation and ubiquitination, on its protein.

The Structure and Function of TMEM232

The structure of TMEM232 is unique in that it is a transmembrane protein that consists of a catalytic domain, a transmembrane segment, and an cytoplasmic tail. The catalytic domain is responsible for the protein's catalytic activity, while the transmembrane segment spans the entire cell membrane and is responsible for its unique localization to various cell types and tissues. The cytoplasmic tail is involved in the protein's stability and localization to the ER.

TMEM232 has several unique features that are relevant to its potential drug target properties, including its ability to interact with various signaling pathways and its unique localization to the ER. The protein's ability to interact with the TGF-β pathway is of particular interest, as this pathway is involved in a wide range of cellular processes, including cell growth, differentiation, and inflammation.

The Potential Therapeutic Applications of TMEM232

TMEM232 has the potential to be a drug target for various diseases due to its unique structure and function. The most promising applications for TMEM232 are its potential as a therapeutic for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and can result in a wide range of cognitive and motor deficits.

In addition to its potential as a neurodegenerative disease therapeutic, TMEM232 may also have applications in other areas, such as cancer and autoimmune disorders. Its unique ability to interact with the TGF-β pathway and its expression in various tissues make it a promising candidate for cancer therapies. Similarly, its ability to localize to the ER and its expression in pancreatic cancer may make it a promising candidate for diagnostic tools and therapies for this disease.

The Biology of TMEM232

TMEM232 is involved in a wide range of cellular processes, including cell signaling, migration, and invasion. It plays a role in several signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and inflammation. TMEM232 is also involved in the regulation of various cellular processes, including cell adhesion, migration, and the delivery of intracellular granules.

In addition to its role in signaling pathways, TMEM232 is also involved in the regulation of various cellular processes

Protein Name: Transmembrane Protein 232

The "TMEM232 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM232 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets